Hologic Inc Stock Price, News & Analysis

Hologic, Inc. has launched the Aptima® SARS-CoV-2/Flu Assay for simultaneous detection of SARS-CoV-2, influenza A, and influenza B. The assay, CE-Marked for Europe and FDA authorized, provides results in approximately three hours and can process over 1,000 tests daily. This multiplex test addresses the overlap of symptoms between these viruses, enhancing testing options as the flu season approaches. Hologic has distributed over 100 million SARS-CoV-2 assays globally.

Hologic, Inc. has partnered with Mediflix to release Carolina, a documentary-style film highlighting the breast cancer journey. Launched during Breast Cancer Awareness Month, this film guides patients from diagnosis to reconstruction. Featuring testimonials from survivors and experts, Carolina aims to enhance understanding of minimally invasive surgical options, such as the Reconstructive Lumpectomy. This innovative approach uses Hologic’s BioZorb marker to improve cosmetic outcomes post-surgery, addressing the emotional concerns of patients.

Black Women’s Health Imperative and Hologic hosted a roundtable, Unmuting Fibroids: Getting Loud for Equal Care, addressing disparities in uterine fibroid care. Experts emphasized that understanding menstruation as a vital health sign is crucial for prioritizing care. Uterine fibroids affect 80% of Black women, leading to severe health implications. Key initiatives include improving education for healthcare providers, advocating for funding legislation, and promoting culturally competent care to reduce disparities. Hologic supports this through its Project Health Equality.

Hologic, Inc. (NASDAQ: HOLX) has announced the acquisition of Bolder Surgical for approximately $160 million. This strategic move aims to diversify Hologic's surgical portfolio by adding advanced vessel sealing devices. Bolder's products are expected to enhance surgical efficiency, particularly in OB/GYN applications, capitalizing on a larger market potential. The acquisition is forecasted to generate $10 million in revenue this year and is expected to be slightly dilutive to earnings in fiscal 2022, with a break-even outlook for fiscal 2023.

Hologic, Inc. (NASDAQ: HOLX) will release its fourth quarter fiscal 2021 financial results on Monday, November 1, after market close. A conference call hosted by management will take place at 4:30 p.m. ET. Interested participants can join by calling 800-458-4121 (US/Canada) or +1 323-794-2093 (international) with access code 2820462. A replay will be available post-call through December 1, 2021. Additionally, the call will be accessible via a live webcast on the company’s website at www.investors.hologic.com.

Hologic, Inc. has launched the Novodiag^® system across Europe, enhancing its molecular diagnostic solutions portfolio. This fully automated diagnostic tool tests for infectious diseases and antimicrobial resistance, following the acquisition of Mobidiag in June 2021. The Novodiag system utilizes real-time PCR and microarray technologies, allowing for rapid multiple pathogen identification from a single sample. It features a CE-IVD test menu for gastrointestinal infections and SARS-CoV-2 detection, with a strong pipeline of future assays.

Hologic, Inc. (NASDAQ: HOLX) has initiated a series of educational initiatives aimed at reducing racial disparities in breast cancer screening. To kick off Breast Cancer Awareness Month, CEO Steve MacMillan will ring the Nasdaq opening bell on October 4. The company is focusing on raising awareness of annual mammograms and addressing inequalities in care, particularly for Black women, who are less likely to receive necessary screenings. Hologic is also collaborating with RAD-AID to improve access to screening services in underserved areas.

Hologic has launched the expanded Omni suite, enhancing gynecological surgical offerings across Europe, Africa, and the Middle East. Key new products include the Omni 30° hysteroscope, Omni Lok cervical seal, and Omni 5 French seal. The advanced hysteroscope features interchangeable sheaths and a long working length for improved versatility in diagnostic and operative procedures. The Omni Lok seal minimizes fluid leakage by an average of 94%, boosting procedural efficiency. These innovations aim to support gynecologists in outpatient environments, adapting to patient needs effectively.

Hologic, Inc. has launched the Hologic Global Women’s Health Index, emphasizing unmet women’s health needs worldwide. With input from over 60,000 women across 116 countries, the index scored a low 54 out of 100 overall, indicating significant healthcare gaps. Key findings reveal that about 1.5 billion women were not tested for critical diseases, while more than 40% haven’t consulted healthcare professionals in the past year. The index identifies five health dimensions linked to women’s life expectancy, calling for global healthcare leaders to prioritize women’s health improvement.